Craig-Hallum initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $21 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Actuate Therapeutics files to sell 3.9M shares of common stock for holders
- Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer
- Actuate Therapeutics initiated with a Buy at H.C. Wainwright
- Actuate Therapeutics completes enrollment in Phase 2 trial of elraglusib